The U.K. is launching a £230 million (US$260 million) project to build a database linking the health records and genetic information of 5 million people, which will be open for discovery research and as a source of clinical trial recruits for academics and companies.
Maxinovel Pharmaceuticals Inc. raised ¥100 million (US$13.8 million) in a series C+ round to develop its candidates for acute myeloid leukemia, solid tumors, and autoimmune diseases.
Jiangsu Cowin Biotech Co. Ltd. has raised ¥1.14 billion (US$156 million) in a listing on the Shanghai STAR Market. Its shares opened at ¥42.96 apiece, plunged over 13% by the middle of the day but closed at ¥43.62 on the first trading day on Oct. 25.
The U.K. is launching a £230 million (US$260 million) project to build a database linking the health records and genetic information of 5 million people, which will be open for discovery research and as a source of clinical trial recruits for academics and companies.
Normunity Inc. emerged from stealth by unveiling $65 million in series A funding and bold plans to tackle one of the critical issues in immuno-oncology. Normunity is based on the research of scientific founder Lieping Chen, of Yale School of Medicine, an early immuno-oncology pioneer who identified and characterized the gene encoding PD-L1 (then called B7-H1) and shortly afterward reporting additional findings that contributed to its recognition as an important target in cancer immunotherapy.
Amplifica Holdings Group Inc. has closed a US$11.8 million series A preferred stock financing, the funds from which will be used to advance the development of its proprietary compounds for the treatment of androgenic alopecia in males and females.
RSS
